Drug Profile
Research programme: heart failure therapeutics - Cordex Pharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Duke University; Johns Hopkins University
- Developer Cordex Pharma
- Class
- Mechanism of Action Nitric oxide donors; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in USA
- 11 Jun 2008 Preclinical trials in Heart failure in USA (unspecified route)